Penn establishes the Center for Precision Engineering for Health with $100 million commitment
Penn announced that it has made a $100 million commitment in its School of Engineering and Applied Science to establish the Center for Precision Engineering for Health.
Penn inventors make the mRNA-based COVID vaccines possible
Drew Weissman, MD, PhD, the Roberts Family Professor of Vaccine Research, and Katalin Karikó, PhD, an adjunct professor of Neurosurgery at Penn, have been awarded multiple prestigious prizes.
Luxturna inventor Jean Bennett starts a new gene therapy company to tackle rare diseases left behind by pharma, VCs
Jean Bennett, who designed and co-developed Luxturna, approved in 2018 for a rare form of blindness, had kept building new gene therapies for eye diseases at her University of Pennsylvania lab.
Katalin Karikó and Drew Weissman named to the 2022 National Inventors Hall of Fame
National Inventors Hall of Fame, in partnership with the United States Patent and Trademark Office, is excited to announce the 2022 Class of Inductees.
Penn engineers will develop on-demand, on-site mRNA manufacturing
With an NSF grant, Penn Engineering researchers are developing a new manufacturing technique that would be able to produce mRNA sequences in a way that removes the need for cryogenic temperatures.
Co-founder of Avisi Technologies named one of the Greater Philadelphia’s Inno Under 25
long with co-founder Brandon Kao, Rui Jing Jiang started Avisi Technologies in 2017, developing VisiPlate, a nanotechnology-enabled ocular implant to treat glaucoma.
At-home COVID-19 results with the click of a smartphone
chers have developed a highly-sensitive rapid antigen test that can detect small loads of SARS-CoV-2
Jean Bennett, M.D., Ph.D., joins REGENXBIO Board of Directors
She will serve as a member of REGENXBIO's Nominating and Corporate Governance Committee.
Inspired by the late Tachi Yamada, Jim Wilson launches new nonprofit targeting underserved ultra-rare diseases
A group of powerhouse biotech leaders is coming together to launch a new nonprofit, one aimed at delivering therapies to rare disease populations they believe pharma is leaving behind.
BioNTech reports promising data on mRNA cocktail in mouse models of colon cancer and melanoma
A BioNTech-led team designed a cocktail of mRNAs that instruct cells to produce four cancer-fighting molecules.